Table 1.
Baseline clinical and electrocardiographic characteristics of the study population
| N = 40 | |
|---|---|
| Men/Women |
31/9 |
| Age |
60.2 ± 10.4 |
| Body surface area (g/m2) |
1.74 ± 0.17 |
| Family history of HCM |
1(2.5%) |
| Family history of SCD |
3 (7.5%) |
| History of syncope |
3 (7.5%) |
| NYHA functional class I/II |
25 (63.5%)/15 (37.5%) |
| Hypertension |
17 (42.5%) |
| Diabetes mellitus |
4 (10%) |
| Smoker |
3 (7.5%) |
| Medications |
|
| Calcium-channel blockers |
13 (32.5%) |
| Beta blockers |
9 (22.5%) |
| ACEi/ARB |
10 (25%) |
| Aspirin |
10 (25%) |
| Diuretics |
6 (15%) |
| SBP/DBP |
125.9 ± 13.7/75.9 ± 8.7 |
| Electrocardiogram |
|
| T wave inversion |
39 (97.5%) |
| Giant T waves ≥10mm | 12 (30%) |
HCM denotes hypertrophic cardiomyopathy; SCD, sudden cardiac death; NYHA, New York Heart Association; ACEi/ARB, angiotension converting esterase inhibitor/angiotensin receptor blocker; S(D)BP, systolic (diastolic) blood pressure; ECG, electrocardiogram.